The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.
 
Debbie Robbrecht
Honoraria - Springer
Consulting or Advisory Role - Axiom Healthcare Strategies; BMS
 
Bernard Doger
No Relationships to Disclose
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Oliver Edgar Bechter
No Relationships to Disclose
 
Maria J. de Miguel
No Relationships to Disclose
 
Maria Vieito
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Roche
 
Dirk Schadendorf
Honoraria - 4SC; Amgen; Array BioPharma; Bristol-Myers Squibb; Daiichi Sankyo Japan; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; Nektar; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daichi-Sankyo; Foundation Medicine; GlaxoSmithKline; Guardant Health; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Ivan Borbath
Honoraria - Bayer (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
Consulting or Advisory Role - Lilly (Inst)
Research Funding - SERVIER (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst)
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Sanofi; Sun Pharma
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Alejo Rodriguez-Vida
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; MSD; Pfizer; Roche
Research Funding - MSD (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Novartis; Pfizer; Roche
 
Wilson H. Miller
Honoraria - Amgen; Bristol Myers Squibb Foundation; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche; Sanofi; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche; Sanofi
Research Funding - Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Canada Research Society (Inst); Canadian Cancer Society Research Institute (CCSRI) (Inst); Canadian Institutes of Health Research (CIHR) (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); MethylGene (Inst); Mimic Technologies (Inst); Novartis (Inst); Ocellaris Pharma (Inst); Pfizer (Inst); Roche (Inst); Samuel Waxman Cancer Research Foundation (Inst); Sanofi (Inst); TERRY FOX RESEARCH INSTITUTE (Inst)
 
Tun Tun Lin
Employment - Pfizer; Sanofi
Stock and Other Ownership Interests - Pfizer; Sanofi
 
Nina Masson
Employment - ITM Stats Company, contracted by Sanofi
 
Clemence Pouzin
Employment - Sanofi/Aventis
Stock and Other Ownership Interests - Sanofi/Aventis
Travel, Accommodations, Expenses - Sanofi/Aventis
 
Rui Wang
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Brigitte Demers
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Patents, Royalties, Other Intellectual Property - Sanofi
 
Amele Amrate
Employment - Sanofi/Aventis
Stock and Other Ownership Interests - Sanofi/Aventis
 
Giovanni Abbadessa
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Patents, Royalties, Other Intellectual Property - Sanofi
 
Matteo Simonelli
No Relationships to Disclose